Ropinirole: A review of its use in the management of Parkinson's disease

Drugs

Volumn 60, Issue 1, 2000, Pages 115-137

  Matheson, A J ^a   Spencer, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BROMOCRIPTINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; DOPAMINE 2 RECEPTOR; ESTROGEN; IBUPROFEN; LEVODOPA; ROPINIROLE; SELEGILINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTHRALGIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; DRUG TOLERABILITY; DYSKINESIA; EXPERIMENTAL MODEL; HUMAN; MONOTHERAPY; NAUSEA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RECEPTOR AFFINITY; REVIEW; SOMNOLENCE; VERTIGO;

EID: 0033877002     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060010-00007     Document Type: Review

References (69)

1. Ropinirole for restless legs syndrome
2. Use of ropinirol as a treatment of the restless legs syndrome
3. Ropinirole for restless legs syndrome (RLS)
4. 2(long) dopamine receptors: Ligand binding and functional assays
5. Pharmacologic profile of ropinirole: A nonergoline dopamine agonist
6. Ropinirole: A dopamine agonist for the treatment of Parkinson's disease
7. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
8. 2 agonist
9. 35S]Guanosine-5-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: Actions of antiparkinsonian and antipsychotic agents
10. 3 receptors
11. The preclinical pharmacology of ropinirole-receptor interactions, antiparkinsonian activity and potential to induce dyskinesia
12. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
13. Dyskinesia induction in MPTP-treated common marmosets following repeated treatment with combinations of L-DOPA and ropinirole
14. 2-dopaminergic agonist ropinirol on supine resting and stimulated circulatory and neuroendocrine variables in healthy volunteers
15. 2-receptor agonist
16. The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients
17. 2-like receptor agonist
18. 18F-dopa PET findings
19. Disposition of ropinirole in animals and man
20. Quetiapine and ropinirole
21. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease
22. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
23. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease
24. The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease
25. Linear pharmacokinetic behaviour of ropinirole during multiple dosing in patients with Parkinson's disease
26. Ropinirole: Summary of product characteristics
27. Pharmacokinetic data for ropinirole
28. The role of dopamine agonists in early Parkinson's disease
29. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole
30. Population pharmacokinetics of ropinirole in patients with Parkinson's disease
31. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
32. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease
33. Ropinirole for the treatment of early Parkinson's disease
34. 2 agonist, as sole dopaminergic therapy in Parkinson's disease
35. Ropinirole for the treatment of early Parkinson disease: A 12-month experience
36. Overnight switch to ropinirole improves activities of daily living in Parkinson's disease patients
37. Response of tremor in untreated Parkinson's disease to therapy with ropinirole
38. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
39. Ropinirole, a placebo-controlled study of efficacy as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa
40. A double-blind comparative study of ropinirole vs bromocriptine in the treatment of Parkinsonian patients not optimally controlled on 1-dopa
41. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
42. Combined levodopa test in the evaluation of efficacy of pergolide and ropinirole
43. The long-term efficacy of ropinirole as an adjunct to L-dopa
44. Ropinirole after pramipexole failure in advanced Parkinson's disease
45. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease
46. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
47. Sleep attacks (sleep episodes) with pergolide
48. Sleep attacks and Parkinson's disease treatment
49. Sudden sleep attacks and antiparkinsonian drugs: A pilot prospective pharmacoepidemiological study
50. The effect of concomitant selegiline on Parkinson's disease patients treated with ropinirole
51. Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist
52. New pharmacotherapy for Parkinson's disease
53. Novel drugs for Parkinson's disease
54. Adjuncts to levodopa therapy: Dopamine agonists
55. Ropinirole in the treatment of Parkinson's disease
56. Levodopa-induced neurotoxicity: Does it represent a problem for the treatment of Parkinson's disease?
57. Treatment of Parkinson's disease should begin with a dopamine agonist
58. Ropinirole: A viewpoint by O. Rascol
59. Dopamine agonists: What is the place of the newer compounds in the treatment of Parkinson's disease?
60. 3 receptor expression as a mechanism of behavioral sensitization of levodopa
61. Motor response to a dopamine D3 receptor preferring agonist compared to amorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine monkeys
62. 18F]dopa PET study
63. Tolcapone suspended in EU and Canada and labelling in US revised
64. Updates from ADRAC
65. Tolcapone guidelines too restrictive?
66. Correlation between L-dopa exposure and dyskinesia in MPTP-treated marmosets. 6th International Congress of Parkinson's Disease and Movement Disorders